AZD6234
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
AstraZeneca · Phase 2 · Active, not recruiting · Enrollment 16
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| AZD6234 (sub-study 1) | n/r | n/r | n/r | n/r | n/r |
| Placebo (sub-study 1) | n/r | n/r | n/r | n/r | n/r |
| AZD9550(sub-study 2 Cohort A) | n/r | n/r | n/r | n/r | n/r |
| Placebo (sub-study 2 Cohort A) | n/r | n/r | n/r | n/r | n/r |
| AZD6234 in combination with AZD9550 (sub-study 2 Cohort B) | n/r | n/r | n/r | n/r | n/r |
| Placebo (sub-study 2 Cohort B) | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.